<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370084</url>
  </required_header>
  <id_info>
    <org_study_id>ITODG04-01</org_study_id>
    <secondary_id>041026</secondary_id>
    <nct_id>NCT00370084</nct_id>
  </id_info>
  <brief_title>Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia</brief_title>
  <official_title>Effects of Itopride Hydrochloride on Gastric Emptying, Glycaemia and &quot;Meal-related&quot; Symptoms in Patients With Type 1 and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Itopride is a new compound that is already marketed in Japan and in some countries of Eastern&#xD;
      Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.&#xD;
      Due to inadequate gastric emptying, these patients often have symptoms of bloating, nausea&#xD;
      and vomiting following ingestion of a meal. The goal of this study is to evaluate the effects&#xD;
      of Itopride on gastric motor function and glycemia in patients with diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a mechanistic study evaluating in a cross-over design the effects of Itopride&#xD;
      hydrochloride.&#xD;
&#xD;
      The primary objective of this study is to evaluate the acute effects of itopride&#xD;
      hydrochloride (200 mg three times daily) on gastric emptying of solid and liquid meal&#xD;
      components in patients with type 1 and type 2 diabetes mellitus. Secondary objectives are to&#xD;
      evaluate the effects of itopride hydrochloride on the glycaemic response to a meal,&#xD;
      &quot;meal-related&quot; upper gastrointestinal symptoms and intragastric meal distribution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying assessment</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Itopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride</intervention_name>
    <description>oral, three times daily</description>
    <arm_group_label>Itopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type-1 and Type-2 diabetic patients&#xD;
&#xD;
          -  18 to 65 years old&#xD;
&#xD;
          -  Glycated haemoglobin level (HbA1c) below 9%&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medications potentially influencing upper gastrointestinal motility or appetite&#xD;
             within one week of the study (e.g. prokinetic drugs, macrolide antibiotics)&#xD;
&#xD;
          -  Exposure to radiation for research purposes during the previous 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Horowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Adelaide, Department of Medicine</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2006</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

